Mauro Waldemar Keiserman

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Megan E. B. Clowse, Daniel J. Wallace, Richard Furie et al. · Arthritis & Rheumatology · 2016 · 236 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

Philip J. Mease, Apinya Lertratanakul, J. Anderson et al. · Annals of the Rheumatic Diseases · 2020 · 233 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

Lars Erik Kristensen, Mauro Waldemar Keiserman, Kim Papp et al. · Annals of the Rheumatic Diseases · 2021 · 143 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

Philip J. Mease, Apinya Lertratanakul, Kim Papp et al. · Rheumatology and Therapy · 2021 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Gender characterization in a large series of Brazilian patients with spondyloarthritis

Hellen M.S. Carvalho, Adriana Bruscato Bortoluzzo, Célio Roberto Gonçalves et al. · Clinical Rheumatology · 2011 · 71 citations

Social Sciences, Gender Studies, Gender +11